Protocol Ledger

NCT07245953 · Phase II · ACTIVE NOT RECRUITING

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Interventional Phase II clinical trial protocol NCT07245953 sponsored by Suzhou HepaThera Biotech Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-05 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07245953
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07245953
Protocol FieldVerified Registry Value
NCT IdentifierNCT07245953
Consolidated Lead SponsorSuzhou HepaThera Biotech Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2025-11-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07245953
Hospital Research SiteLocationSite Profile
Sichuan Provincial People's HospitalChengdu, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI